[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627461":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":34,"slug":7,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Mario Nuvolone, MD","CONTACT","0382502935","m.nuvolone@smatteo.pv.it",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Fondazione IRCCS Policlinico San Matteo","RECRUITING","Pavia","27100","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],9.15917,45.19205,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":12,"phoneExt":7,"email":13},"Mario Nuvolone",{"type":32,"investigatorFullName":30,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100627461",false,"NCT07448935","One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS","ALPS","Inclusion Criteria:\n\n* Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma\n* Planned peripheral blood sampling +\u002F- bone marrow aspiration\n* Age \\> 18 years\n* Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.\n\nExclusion Criteria:\n\n* Undefined monoclonal gammopathy or non-AL amyloidosis\n* Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy\n* Age \\\u003C18 years\n* Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.","ALL","18 Years","99 Years",{"count":44,"type":45},100,"ESTIMATED","OBSERVATIONAL","By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.",[49,50,51],"AL Amyloidosis","POEMS Syndrome","Multiple Myeloma","2026-04-30",{"date":54,"type":55},"2026-05-06","ACTUAL",{"date":57,"type":55},"2025-11-28",{"date":59,"type":45},"2026-06-30",{"name":5,"class":6},1]